News & Updates

What are the risk factors for relapse after methotrexate dose reduction?
What are the risk factors for relapse after methotrexate dose reduction?
25 Apr 2023

For patients with rheumatoid arthritis, a history of cardiovascular disease, gastrointestinal disease, or liver disease, as well as prior use of nonsteroidal anti-inflammatory drugs can contribute to an increased risk of relapse after methotrexate dose reduction, as suggested in a study.

What are the risk factors for relapse after methotrexate dose reduction?
25 Apr 2023
Psilocybin shows therapeutic potential for depression
Psilocybin shows therapeutic potential for depression
24 Apr 2023

For cancer patients with depression, treatment with a single dose of psilocybin appears to yield rapid and meaningful improvements in depressive symptoms, as shown in a phase II study.

Psilocybin shows therapeutic potential for depression
24 Apr 2023
Vonoprazan-amoxicillin combo on par with B-quadruple therapy for H. pylori infection
Vonoprazan-amoxicillin combo on par with B-quadruple therapy for H. pylori infection
23 Apr 2023

Ten-day treatment with vonoprazan 20 mg twice/day plus amoxicillin 750 mg four times/day (VHA-dual) as a first-line therapy for Helicobacter pylori infection results in satisfactory eradication rate of >90 percent, fewer adverse events (AEs), and similar adherence when compared with bismuth quadruple therapy (B-quadruple), results of a study have shown.

Vonoprazan-amoxicillin combo on par with B-quadruple therapy for H. pylori infection
23 Apr 2023
Sleep disruption after COVID tied to dyspnoea, other post-acute sequelae
Sleep disruption after COVID tied to dyspnoea, other post-acute sequelae
22 Apr 2023 byElvira Manzano

Sleep disruption following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness in the CircCOVID cohort sub-study presented at ECCMID 2023.

Sleep disruption after COVID tied to dyspnoea, other post-acute sequelae
22 Apr 2023
Molnupiravir speeds up recovery, reduces viral load of vaccinated COVID-19 patients
Molnupiravir speeds up recovery, reduces viral load of vaccinated COVID-19 patients
21 Apr 2023 byStephen Padilla

In vaccinated adults with COVID-19 who are at higher risk of adverse outcomes, treatment with molnupiravir in addition to usual care falls short of reducing the rates of hospitalizations and deaths, as shown by the results of the PANORAMIC study.

Molnupiravir speeds up recovery, reduces viral load of vaccinated COVID-19 patients
21 Apr 2023